March 12th 2025
Compared to placebo, there was a 70% reduction in IgE levels in children ages 0.5 to 6 after 16 weeks of therapy.
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Melanoma Tumor Board: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies
March 31, 2025
Register Now!
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Revolutionizing Atopic Dermatitis (RAD) Conference 2025
June 6-7, 2025
Register Now!
Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient
July 26, 2025
Register Now!
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis
View More
Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?
View More
Studies further condemn UVA reputation
May 1st 2002New Orleans - The role of UVA radiation in generating a number of diseases is now much better understood, Robert Bissonnette, M.D., said at the annual meeting of the American Academy of Dermatology. "If you go back 10 years, we knew a lot about UVB but little about UVA. Now, we know that it can cause skin cancer in animals," he said.
Lesion size, location dictate decision on pediatric surgery
April 1st 2002New Orleans - Timing is key for a successful outcome when performing dermatologic surgery in pediatric patients, and lesion size and location are the two most important variables factoring into the equation, Annette M. Wagner, M.D., said at the annual meeting of the American Academy of Dermatology.
Systemic CD often an elusive diagnosis
April 1st 2002New Orleans - Systemic contact dermatitis may present with a variety of eczematous and noneczematous cutaneous reaction patterns and may be an overlooked diagnosis unless clinicians maintain an index of suspicion that systemic exposure to a contact allergen is driving the skin eruption, Donald V. Belsito, M.D., said at the annual meeting of the American Academy of Dermatology.
Infliximab finds utility in management of pyoderma gangrenosum
April 1st 2002New Orleans - The experiences of an expanding series of patients indicate infliximab (Remicade) is a valuable therapy for the management of pyoderma gangrenosum (PG), Marketa Limova, M.D., said at the annual meeting of the American Academy of Dermatology.